Lyell Immunopharma (LYEL) to Release Quarterly Earnings on Wednesday

Key Points

• Lyell Immunopharma is set to announce its Q2 2025 earnings on August 6th, with expectations of a loss of $0.19 per share.
• The company's last earnings report showed a loss of $3.60 per share, which exceeded analyst expectations by $0.20.
• Recently, Acadian Asset Management increased its stake in Lyell Immunopharma by 204.2%, owning approximately 66.05% of the company's stock as of the latest report.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) is anticipated to issue its Q2 2025 quarterly earnings data before the market opens on Wednesday, August 6th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($3.60) EPS for the quarter, beating analysts' consensus estimates of ($3.80) by $0.20. The company had revenue of $0.01 million during the quarter. Lyell Immunopharma had a negative return on equity of 73.66% and a negative net margin of 514,649.22%. On average, analysts expect Lyell Immunopharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Lyell Immunopharma Stock Performance

Shares of LYEL traded down $0.79 during midday trading on Friday, hitting $11.02. The company had a trading volume of 19,787 shares, compared to its average volume of 72,573. The company's 50-day simple moving average is $9.96 and its 200-day simple moving average is $10.44. The firm has a market capitalization of $163.21 million, a P/E ratio of -0.44 and a beta of -0.19. Lyell Immunopharma has a 1 year low of $7.65 and a 1 year high of $32.40.

Institutional Trading of Lyell Immunopharma

A hedge fund recently raised its stake in Lyell Immunopharma stock. AQR Capital Management LLC increased its holdings in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) by 773.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 174,279 shares of the company's stock after buying an additional 154,327 shares during the quarter. AQR Capital Management LLC owned about 0.06% of Lyell Immunopharma worth $94,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 66.05% of the company's stock.

Analyst Upgrades and Downgrades

LYEL has been the topic of several research reports. HC Wainwright reissued a "neutral" rating and issued a $10.00 target price on shares of Lyell Immunopharma in a report on Tuesday, June 24th. Wall Street Zen raised Lyell Immunopharma to a "hold" rating in a report on Friday, June 6th.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.